Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

their blood pressure improves—but their anti-hypertensive medications are never adjusted, so they faint or experience low ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Oprah Winfrey opens up on her podcast about her weight-loss journey with anti-obesity GLP-1 medications while chatting with doctors and guests. Plus, the media icon shares how her opinion of "thin ...